Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wilson H Miller

Showing results (131-140 of 168) with videos related to

Pageof 17
Sort By:
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 5, 2014
Methods for sample acquisition and processing of serial blood and tumor biopsies for multicenter diffuse large B-cell lymphoma clinical trialsTorsten Holm Nielsen, Zuanel Diaz, Rosa Christodoulopoulos, et al.
European Journal of Cancer (Oxford, England : 1990)|May 19, 2022
Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 studyMichele Maio, Mayur M Amonkar, Josephine M Norquist, et al.
Cell Death and Differentiation|February 18, 2026
RAB1A is a novel vulnerability in uveal melanoma revealed by dual inhibition of MNK1/2 and mTORRaúl E Flores-González, Christophe Goncalves, Noah Wirasinghe, et al.
The Lancet. Oncology|March 4, 2014
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety studyJames Larkin, Michele Del Vecchio, Paolo A Ascierto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2017
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III TrialJames Larkin, David Minor, Sandra D'Angelo, et al.
The Journal of Clinical Investigation|August 24, 2023
Peroxisome disruption alters lipid metabolism and potentiates antitumor response with MAPK-targeted therapy in melanomaFan Huang, Feiyang Cai, Michael S Dahabieh, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 22, 2018
Translational control in the tumor microenvironment promotes lung metastasis: Phosphorylation of eIF4E in neutrophilsNathaniel Robichaud, Brian E Hsu, Roman Istomine, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2017
Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF<sup>V600</sup> mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysisChristian U Blank, James Larkin, Ana M Arance, et al.
Lancet (London, England)|June 28, 2012
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialAxel Hauschild, Jean-Jacques Grob, Lev V Demidov, et al.
European Journal of Cancer (Oxford, England : 1990)|October 9, 2020
High mortality among hospital-acquired COVID-19 infection in patients with cancer: A multicentre observational cohort studyArielle Elkrief, Antoine Desilets, Neha Papneja, et al.
Pageof 17

Showing results (131-140 of 168) with videos related to

Sort By:
Pageof 17
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 5, 2014
Methods for sample acquisition and processing of serial blood and tumor biopsies for multicenter diffuse large B-cell lymphoma clinical trialsTorsten Holm Nielsen, Zuanel Diaz, Rosa Christodoulopoulos, et al.
European Journal of Cancer (Oxford, England : 1990)|May 19, 2022
Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 studyMichele Maio, Mayur M Amonkar, Josephine M Norquist, et al.
Cell Death and Differentiation|February 18, 2026
RAB1A is a novel vulnerability in uveal melanoma revealed by dual inhibition of MNK1/2 and mTORRaúl E Flores-González, Christophe Goncalves, Noah Wirasinghe, et al.
The Lancet. Oncology|March 4, 2014
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety studyJames Larkin, Michele Del Vecchio, Paolo A Ascierto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2017
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III TrialJames Larkin, David Minor, Sandra D'Angelo, et al.
The Journal of Clinical Investigation|August 24, 2023
Peroxisome disruption alters lipid metabolism and potentiates antitumor response with MAPK-targeted therapy in melanomaFan Huang, Feiyang Cai, Michael S Dahabieh, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 22, 2018
Translational control in the tumor microenvironment promotes lung metastasis: Phosphorylation of eIF4E in neutrophilsNathaniel Robichaud, Brian E Hsu, Roman Istomine, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2017
Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF<sup>V600</sup> mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysisChristian U Blank, James Larkin, Ana M Arance, et al.
Lancet (London, England)|June 28, 2012
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialAxel Hauschild, Jean-Jacques Grob, Lev V Demidov, et al.
European Journal of Cancer (Oxford, England : 1990)|October 9, 2020
High mortality among hospital-acquired COVID-19 infection in patients with cancer: A multicentre observational cohort studyArielle Elkrief, Antoine Desilets, Neha Papneja, et al.
Pageof 17